Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAU 2020 | PREFERE: active surveillance in prostate cancer

Peter Albers • 15 Jul 2020
EAU 2020
Genitourinary Cancer Prostate Cancer Olaparib
PREFERE

Peter Albers, MD, University Hospital of Düsseldorf, Düsseldorf, Germany, describes the results of the PREFERE trial (NCT01717677), evaluating active surveillance in low- and early intermediate-risk prostate cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Peter Albers

3:14
Novel MRI approach for prostate cancer screening
Peter Albers • 8 Jul 2021
3:40
Surgery in metastatic germ cell tumors to reduce disease burden and improve long-term outcomes
Peter Albers • 8 Jul 2021
1:34
Current state of prostate cancer screening in Europe
Peter Albers • 8 Jul 2021
1:57
Challenges in prostate cancer screening
Peter Albers • 8 Jul 2021

Related Videos

0:57
Real-world outcomes of 177Lu-PSMA-617 in mCRPC
Hannah McManus • 8 Apr 2024
0:38
Emerging combinatory immunotherapies show promise for mCRPC
Hannah McManus • 8 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals